However, as clinical relevance of these findings is debatable, structural application of icepacks in patients undergoing 177Lu-PSMA therapy in advanced prostate cancer should remain optional, but most likely does not contribute to reduction of xerostomia. This evidence concerns the gene FOLH1 and xerostomia.